Last reviewed · How we verify

NCT04444531

Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia

Completed Last updated 25 November 2020
What this trial tests

trial in COVID-19 Pneumonia in 18 participants. Completed in 26 May 2020.

Timeline
20 March 2020
Primary endpoint
19 May 2020
26 May 2020

Quick facts

Lead sponsorInstitut d'Investigació Biomèdica de Girona Dr. Josep Trueta
StatusCompleted
Study typeOBSERVATIONAL
Enrollment18
Start date20 March 2020
Primary completion19 May 2020
Estimated completion26 May 2020
Sites1 location across Spain

Conditions studied

Sponsor

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Who can join

Eligibility, any sex, with COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to determine whether the use of ozone autohemotherapy is associated with a decrease in time to clinical improvement

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study.
    Hernández A, Viñals M, Pablos A, Vilás F, et al · · 2021 · cited 27× · PMID 33310665 · DOI 10.1016/j.intimp.2020.107261

Verify or expand the search:

Other recruiting trials for COVID-19 Pneumonia

Currently open trials in the same condition.

Other Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04444531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing